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ABSTRACT 
Several neuropeptidergic systems act as modulators of cognitive performances. Among them, 
nociceptin, an opioid-like peptide also known as orphanin FQ (N/OFQ), has recently gained 
attention. Stimulation of its receptor, the N/OFQ opioid receptor (NOP), which is expressed in 
brain regions involved in emotion, memory and stress response, has inhibitory effects on the 
acquisition and/or consolidation of spatial and emotional memory in rodents. Recently, 
N/OFQ was also proposed to be linked to the pathogenesis of Post-Traumatic Stress Disorder 
in humans. However, until now the effect of the activation of the N/OFQ-NOP system on 
already consolidated memory, such as during retrieval and reconsolidation phases, has never 
been explored. In the present study, we investigated the consequences of systemic injection of 
NOP agonists or i.c.v. injection of the N/OFQ peptide on the retrieval and the reconsolidation 
of contextual fear memory in mice. We demonstrate that the activation of the N/OFQ system 
impairs the reconsolidation of context-dependent but not cue-dependent aversive memories. 
We also show that this amnestic effect is associated with decreased c-Fos expression in the 
hippocampus and amygdala. Our data thus provide the first evidence that the NOP receptor 
could be targeted during the reconsolidation process to weaken maladaptive memories. The 
N/OFQ-NOP system might constitute in the future an interesting pharmacological target for 
interfering with so-called “pathological memories”, in particular those involving maladaptive 
contextual memories.  
Keywords: nociceptin/orphanin FQ, NOP receptor, contextual fear memory, reconsolidation, 
hippocampus 
 
3 
 
1. INTRODUCTION 
Long-term memory is a dynamic process. During memory retrieval the memory trace returns 
to a labile state and has then to be re-stabilized or reconsolidated to ensure long-term storage 
(Alberini and Ledoux, 2013; Nader, 2015; Nader et al., 2000). Interfering with the 
reconsolidation process is thus a way to alter the original memory. In humans, inhibiting 
reconsolidation is a promising strategy to treat disorders that involve maladaptive memories 
such as post-traumatic stress disorder (PTSD), phobia or addiction (Parsons and Ressler, 
2013; Schwabe et al., 2014). Targeting reconsolidation using pharmacological agents, such as 
adrenergic antagonists, has been successful in attenuating memories in animal models of 
aversive or appetitive conditioning (Reichelt and Lee, 2013). This approach has also shown 
promising results in humans suffering from PTSD or phobia. However its effectiveness has 
also been questioned in some clinical populations (Kroes et al., 2016), highlighting the 
necessity to better understand the mechanism of memory reconsolidation and to identify new 
pharmacological targets to attenuate maladaptive memories in humans.  
Nociceptin/orphanin FQ (N/OFQ) is a 17-amino acid neuropeptide related to the opioid 
family (Meunier et al., 1995; Reinscheid et al., 1995). However it does not interact with 
classical mu, delta and kappa opioid receptors but with another opioid-like G-protein-coupled 
receptor called ORL1 or NOP (Meunier et al., 2000).  Consistent with its widespread 
distribution in the central nervous system N/OFQ has been shown to modulate many 
physiological functions in rodents such as pain, feeding, cardiovascular control, reward, 
stress/anxiety and depression-like behavior (Calo et al., 2000; Lambert, 2008; Zaveri, 2016). 
In addition, it has been suggested that endogenous N/OFQ could negatively modulate learning 
and memory processes (Manabe et al., 1998). Supporting this idea, NOP agonists have been 
shown to interfere with memory acquisition and consolidation in many learning tasks in pre-
clinical animal models (Andero, 2015; Ouagazzal, 2015). More specifically, the injection of 
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N/OFQ i.c.v. or of small molecule NOP agonists i.p. inhibits memory acquisition and/or 
consolidation in spatial, contextual and recognition memory tasks such as the Morris water 
maze (Higgins et al., 2002; Kuzmin et al., 2009), fear conditioning (Andero et al., 2013; 
Fornari et al., 2008; Goeldner et al., 2009; Mamiya et al., 2003), passive avoidance 
(Hiramatsu and Inoue, 1999; Liu et al., 2007; Mamiya et al., 1999) and novel object 
recognition (Goeldner et al., 2008). N/OFQ was also found to impair learning when injected 
directly in the dorsal hippocampus  (Goeldner et al., 2008; Redrobe et al., 2000; Sandin et al., 
1997; Sandin et al., 2004) or the amygdala (Andero et al., 2013; Roozendaal et al., 2007). 
Moreover, alterations in the endogenous N/OFQ system have been described in mouse and rat 
models of PTSD (Andero et al., 2013; Zhang et al., 2012; Zhang et al., 2015). Finally, a recent 
study identified a single-nucleotide polymorphism of the NOP receptor associated with 
increased PTSD symptoms in individuals exposed to child abuse (Andero et al., 2013). 
Altogether, these data suggest that the N/OFQ system could be targeted to interfere with 
maladaptive memories associated with PTSD. However, to further validate this hypothesis, 
the efficacy of NOP agonists to inhibit memory reconsolidation remains to be determined. 
While consolidation and reconsolidation processes show many similarities, they also involve 
specific molecular mechanisms, which take place in distinct brain regions according to 
different kinetics (Alberini, 2005; Li et al., 2013; von Hertzen and Giese, 2005). Therefore, in 
the present study we tested whether, similarly to their well-characterized effect on learning 
and memory consolidation, NOP agonists are able to interfere with the reconsolidation of fear 
memory.  
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2. MATERIALS AND METHODS 
2.1 Animals  
A total of 176 C57BL/6 male mice (10-12 week-old, Janvier Labs, Le Genest-Saint-Isle, 
France) were used. They were housed in collective cages (5 per cage) in a room with 
controlled temperature (21–23°C), and a 12-h light/dark cycle (8.00 am-8.00 pm). Food and 
water were provided ad libitum. All experiments were carried out in strict accordance with the 
European guidelines for the care of laboratory animals (European Communities Council 
Directive 86/609/ECC) and approved by the local ethical committee and the French Ministry 
of Education and Research (#1992-2015092911113438). All efforts were made to minimize 
animal discomfort and to reduce the number of animals used. 
 
2.2 Drugs  
Ro 65-6570 and N/OFQ were synthesized and purified in house (University of Ferrara) using 
previously described protocols (Guerrini et al., 1997; Wichmann et al., 1999). AT-403 was 
synthesized at Astraea Therapeutics. MK-801was purchased from Sigma (St. Quentin 
Fallavier, France). All small molecules were first prepared as stock solutions in 100% DMSO 
then diluted in saline (0.9% NaCl, maximal final DMSO concentration was 2%). For each 
experiment, vehicle refers to the control saline solution with an equivalent percentage of 
DMSO. The volume for intra-peritoneal (i.p.) injections was 10 ml/kg. N/OFQ peptide was 
prepared fresh in saline for intra-cerebro-ventricular (i.c.v.) injections. The volume for i.c.v. 
injections was 2µl. 
 
2.3 Surgery 
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The mice were anaesthetized with chloral hydrate (400 mg ⁄ kg, i.p.) and placed in a 
stereotactic apparatus (David Kopf Instruments, Tujunga, CA, USA). Guide cannulae were 
implanted into the lateral ventricle according to the following coordinates: AP 0 mm, Lat ± 1 
mm from bregma, and DV−2 mm from skull as previously described (Mouledous et al., 
2010). After surgery, animals were allowed to recover for 7 to 9 days in their home cage 
before the start of the behavioral experiments. At the end of the behavioral experiments, all 
mice were deeply anaesthetized with an overdose of pentobarbital (Ceva Santé Animale, 
Libourne, France) and their brains removed for histological verification of cannulae 
placement as previously described (Massaly et al., 2013).  
 
2.4 Fear conditioning 
Conditioning was done in a rectangular conditioning chamber (length 35 cm, width 20 cm, 
height 25 cm) with a stainless steel rod ﬂoor as previously described (Daumas et al., 2004). 
The experimental device was lit by a 60-W white bulb. Two black-and-white patterns faced 
the conditioning chamber. The conditioning chamber was cleaned with 70% aqueous ethanol 
before each training session. For the consolidation experiment, conditioning consisted in a 
single session with two trials. After a 120 s exploration period, the sound (85 dB) was emitted 
for 30 s and a foot shock (0.7 mA) was superposed during the last 2 s of the tone. This 
sequence was repeated twice. Thirty seconds after the last foot shock, the mice were removed 
from the chamber and returned to their home cage. Twenty-four hours after, the mice were 
individually tested for freezing to the context in the conditioning chamber for 4 min. Two 
hours later, they were tested for freezing to the tone in a modiﬁed context consisting in a 
triangular chamber, with white Plexiglas walls and floor. The new chamber was washed with 
1% acetic acid and lit by a 40 W red bulb. Two minutes after their placement in the modiﬁed 
context, the tone was presented for 2 min. All experiments were videotaped. Freezing, deﬁned 
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as the lack of all movement other than respiration and heart-beat, was scored manually in 5 s 
bins by an experimenter blind to the treatment groups. 
For the contextual fear memory reconsolidation experiments, conditioning was similar except 
that no sound was emitted. Twenty-four hours after learning, the mice were subjected to a 
memory retrieval session by exposing them to the conditioning context for 2 min. This 
retrieval session was immediately followed by drug treatment. Twenty-four hours after 
memory retrieval, mice were individually checked for freezing to the context in the 
conditioning chamber for 4 min. Freezing was scored during both the 2 min retrieval and the 4 
min test sessions. 
For the tone fear memory reconsolidation experiment, another set-up was used that allowed 
the use of 3 different contexts. Conditioning was done inside a white chamber in a squared 
box (25x25 cm, height 34.5 cm) with a stainless steel rod ﬂoor and cleaned with 70% ethanol 
between each mouse. It consisted in a single session with two trials as described above.  
Twenty-four hours after, the recall was performed inside a grey box in a cylinder (diameter 
25cm, height 34.5cm) with a smooth floor and cleaned with 1% acetic acid between each 
mouse. The mice were subjected to this memory retrieval session by letting them explore the 
context for one minute then exposing them to the sound for 30 seconds. This retrieval session 
was immediately followed by drug treatment. Twenty-four hours after memory retrieval, mice 
were individually tested for freezing to the sound in a third context, consisting in a triangular 
box (width 25cm, length 31cm, height 34.5cm) with rough floor and black and white striped 
walls, cleaned with water between each mouse. During this test, the mice were exposed for 
one minute to the context alone, and then for two minutes to the sound. Freezing was scored 
automatically using the PolyFear 5.4 tight infrared frame-based software (Imetronic, Pessac, 
France). 
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2.5 Rotarod 
Rotarod performance was measured using an Ugo Basile rotarod apparatus (Gemonio, Italy, 
length, 8.5 cm; diameter, 7 cm). On day 1, mice were trained to remain on the rotarod rotating 
at 12 rpm for 120 s. On day 2, mice were given three trials (12 rpm, up to a maximum of 120 
s) 20 min after agonist treatment and the average score (time before falling from the rod) was 
used in the final analysis. 
 
2.6 Elevated plus maze 
The apparatus (Imetronic, Pessac, France) consisted of a plus-shaped track with 2 closed and 
2 open arms (30 x 10 x 20 cm) that extended from a central platform (10 x 10 cm). The 
apparatus was elevated 50 cm above the floor. Each trial began when the mouse was placed in 
the central zone and lasted 5 min. The number of entries into closed and open arms and the 
time spent in each arm were monitored automatically based on infrared beam crossing. The 
maze was cleaned with 70% ethanol between each mouse to remove olfactory cues.  
 
2.7 Immunohistochemistry 
c-Fos immunohistochemistry was performed as previously described (Mouledous et al., 2010) 
with slight modifications. Briefly, mice were overdosed with pentobarbital 90 min after 
memory retrieval and perfused transcardially with saline followed by 4% paraformaldehyde 
(Prolabo, Paris, France). The brains were postfixed overnight at 4°C then transferred in 0.1M 
phosphate buffer containing 40% (w/v) sucrose and 0.1% (w/v) sodium azide at 4°C. 40 µm 
thick coronal sections were cut in a SM2010 R microtome (Leica biosystems, Nanterre, 
France) and stored in cryoprotectant at -20°C. Sections were incubated with 0.3% H2O2 in 
PBS for 30 min at room temperature then blocking was performed for 2 h in PBS containing 
0.25% Triton X-100 and 3% normal goat serum (Vector Laboratories, Burlingame, CA, 
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USA). Sections were then incubated with rabbit anti-c-Fos antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) diluted 1:5 000 in the same buffer for 48 h at 4°C. 
After washing with PBS, sections were incubated with biotinylated goat anti-rabbit antibody 
(Vector Laboratories) diluted 1:600 in blocking solution for 2 h at room temperature. Sections 
were then placed in horseradish peroxidase avidin-biotin complex (Vectastain ABC kit, 
Vector Laboratories) diluted in PBS 0.5 % Triton X-100 for 1 h at room temperature. Sections 
were finally stained in 3,3’-diaminobenzidine substrate kit (Vectastain DAB kit, Vector 
Laboratories) for 6 min according to manufacturer instructions. Sections were mounted on 
gelatin-coated slides and counterstained with Nuclear fast red (Vector Laboratories). Sections 
were viewed under a Leica CTR 600 wide-field microscope (Nanterre, France) and the 
Mercator software (Explora Nova, La Rochelle, France) was used to delimit the areas of 
interest (x5 objective) and count c-Fos positive nuclei (40x objective). For each region, 6 
sections per animal were analyzed by an experimenter blind to the treatment groups. 
  
2.8 Statistics 
All results are presented as means ± SEM. Data were analyzed by Student t-test, one- or two-
way ANOVA followed by Bonferroni post hoc as indicated in figure legends, using GraphPad 
Prism (GraphPad Software, Inc., San Diego, CA, version, 5.01).  
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3. RESULTS 
3.1 Systemic NOP agonist treatment inhibits contextual fear memory consolidation 
We first verified that, similarly to other NOP agonists, the full agonist Ro 65-6570 (Asth et 
al., 2016; Wichmann et al., 1999) was able to inhibit contextual fear memory consolidation. 
Mice were submitted to a fear conditioning protocol consisting in 2 pairings of an auditory CS 
with a footshock immediately followed by systemic (i.p.) administration of vehicle or Ro 65-
6570 at the dose of 0.1 or 1 mg/kg (Figure 1A). On the next day, freezing to the conditioning 
context was evaluated. A one-way ANOVA revealed an effect of drug treatment (F2,27=3.548, 
p=0.043) and post-hoc tests demonstrated a significant decrease in freezing (p<0.05) in 
animals that had received the 1 mg/kg but not 0.1 mg/kg dose (Figure 1B). Two hours after 
contextual memory testing, animals were exposed to the auditory CS in a modified context. 
The level of freezing to the tone was similar between the 3 groups of mice (One-way 
ANOVA, F2,27=0.094, p=0.91) (Figure 1C). Based on this last observation we decided to 
focus our investigations on the reconsolidation of contextual, rather than auditory, fear 
memory. 
 
3.2 NOP agonist treatment inhibits contextual fear memory reconsolidation 
Mice were trained to associate the context to the footshocks without auditory CS. The day 
after training, mice were exposed to the conditioning context for 2 minutes in order to 
reactivate the memory trace. Drugs were injected immediately after this retrieval session with 
the aim to interfere with the reconsolidation process. Memory strength was evaluated 24h 
later, by measuring the freezing to the conditioning context (Figure 2A). In addition to Ro 65-
6570 (1 mg/kg), the NMDA receptor antagonist MK-801 (0.1 mg/kg) was also tested as a 
positive control (Charlier and Tirelli, 2011). Both treatments induced a significant decrease in 
freezing during the retention test whereas there was no difference between groups in the level 
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of freezing during the memory retrieval session (Figure 2B). A two-way repeated measures 
ANOVA revealed a significant interaction between time and drug treatment (F2,21=3.24, 
p=0.048) and a significant effect of time (F1,21=45.24, p<0.001) but no significant effect of 
drug treatment (F2,21= 2.908, p= 0,077). Post-hoc tests demonstrated a significant decrease in 
freezing in animals treated during the reconsolidation period with MK-801 (p<0.05) or Ro 65-
6570 (p<0.01) and no difference between MK-801 and Ro 65-6570 treated groups (p>0.05). 
Importantly, Ro 65-6570 treatment was ineffective if the retrieval session was omitted (Figure 
2C, unpaired t test, p=0.933), indicating that memory reconsolidation had to be triggered in 
order to observe the amnestic effect of the NOP agonist. Since NOP agonists are known to 
exert anxiolytic effects (Witkin et al., 2014) that could interfere with the expression of 
freezing behavior, we also looked for a putative residual anxiolytic effect of Ro 65-6570 24h 
after treatment. Ro 65-6570 treated mice behaved as controls in the elevated plus-maze test 
(Suppl Figure 1), in agreement with the fact that treatment without memory reactivation does 
not affect freezing. Next, we conducted another experiment to test a lower dose of 0.1 mg/kg 
together with the effective 1 mg/kg dose (Figure 2D). A one-way ANOVA analysis revealed a 
significant effect of drug treatment (F2,21= 3.661, p= 0.043). Post-hoc tests demonstrated a 
significant decrease in freezing of animals treated with Ro 65-6570 at 1 mg/kg (p<0.05) but 
not at 0.1 mg/kg (p>0.05). Higher doses were not tested since preliminary experiments 
showed that they induced a sedative effect. This effect was evident in the rotarod test for a 
dose of 3 mg/kg, whereas the 1 mg/kg dose did not induce motor impairment (Suppl Figure 
2). Finally, mice treated with vehicle or 1 mg/kg Ro 65-6570 were exposed again to the 
conditioning context 7 days after the first memory test (Figure 2E). The level of freezing 
remained significantly lower in the Ro 65-6570-treated group (unpaired t-test, p=0.045), 
indicating that the amnestic effect was stable for at least one week.   
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In order to further confirm that the NOP receptor can be targeted to inhibit memory 
reconsolidation, we tested two other highly selective NOP agonists unrelated to Ro 65-6570, 
using the same procedure as the one described in figure 2A (Figure 3A). In a first experiment 
we injected the N/OFQ peptide itself in the lateral ventricle immediately after memory 
retrieval (Figure 3B). A one-way ANOVA revealed an effect of drug treatment (F2,24=4.65, 
p=0.019) and post-hoc tests demonstrated a significant decrease in freezing (p<0.05) in 
animals that had received 3 nmoles of the peptide. Although animals treated with 1 nmole of 
the peptide showed less freezing than control mice this decrease was not statistically 
significant (p>0.05). In a second experiment, we tested i.p. administration of a new highly 
potent and selective small molecule NOP agonist AT-403 (Figure 3C). AT-403 has high 
binding affinity for the NOP receptor (Ki 1.13 nM), >100-fold selectivity versus the other 
opioid receptors, and is a full agonist at the NOP receptor (Ferrari et al., 2017). A one-way 
ANOVA revealed an effect of drug treatment (F2,22=4.846, p=0.018) and post-hoc tests 
demonstrated a significant decrease in freezing (p<0.05) in animals that had received the 0.1 
mg/kg dose as well as a significant difference between the 0.1 mg/kg and 0.03 mg/kg groups 
(p<0.05) but not between the 0.03 mg/kg and vehicle groups (p>0.05). Altogether these 
results demonstrate that activating central NOP receptors during memory reconsolidation 
interferes with this process, thus resulting in a significant decrease in contextual fear memory 
retention. 
 
3.3 NOP agonist treatment does not interfere with contextual fear memory retrieval 
The memory impairments that we observed thus far following Ro65-6570 administration 
cannot be attributed to a drug effect on memory acquisition or retrieval since it was injected 
after learning (consolidation experiment) or after memory recall (reconsolidation experiment). 
In the next experiment we asked whether NOP agonist administration could interfere with 
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memory retrieval by injecting Ro 65-6570 20 min before, instead of immediately after, animal 
re-exposure to the conditioning context (Figure 4A). Memory strength was also evaluated 24h 
later, by measuring the freezing to the conditioning context. Freezing levels during the 
retrieval session were similar between NOP agonist and vehicle-injected mice (Figure 4B). 
When tested for memory retention 24h later, Ro 65-6570-treated mice showed a lower level 
of freezing compared to control mice. However, unlike for the post-retrieval injection 
experiment, a two-way repeated measures ANOVA revealed a significant effect of time 
(F1,18=15.24, p<0.01) but no significant interaction between time and drug treatment 
(F1,18=0.763, p=0.394), and only a trend for a significant effect of treatment (F1,18=4.357, 
p=0.051). Overall these data suggest that Ro 65-6570 injection prior to re-exposure to the 
conditioning context does not affect memory retrieval. Moreover, we could not demonstrate a 
significant inhibitory effect on memory reconsolidation under these administration conditions. 
 
3.4 NOP agonist treatment following memory retrieval inhibits c-Fos expression in the 
hippocampus and the amygdala 
The NOP receptor is widely distributed in the central nervous system (Mollereau and 
Mouledous, 2000) and therefore the application of NOP agonist in our experiments could 
interfere with neuronal processes in different brain regions involved in contextual fear 
memory. To address this issue we investigated the effect of post-retrieval Ro 65-6570 
administration in the two main brain areas associated with contextual and emotional memory, 
namely the hippocampus and the amygdala respectively (Baldi and Bucherelli, 2015; 
Izquierdo et al., 2016). Conditioning and drug administration procedures were similar to those 
in the reconsolidation experiment (Figure 2A) except that animals were sacrificed 90 min 
after memory retrieval. Expression of the immediate early gene c-Fos was detected by 
immunohistochemistry as a molecular correlate of neuronal plasticity. In the dorsal 
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hippocampus, Ro 65-6570 administration resulted in a significant decrease in the density of c-
Fos positive cells in the CA3 (37.3%, p=0.034) and CA1 (61.9%, p=0.041) regions but not in 
the dentate gyrus (DG, p=0.25) (Figure 5A). In the ventral hippocampus, NOP agonist 
treatment significantly reduced densities of c-Fos cells in CA1 (48.2%, p=0.029) but not in 
CA3 (p=0.202) nor in the DG (p=0.668) (Figure 5B). In the amygdala, Ro 65-6570-induced 
decrease in the density of c-Fos positive cells was significant in the central region (CeA, 
54.5%, p=0.016) whereas in the basolateral part (BLA) the 47.5% decrease did not reach 
statistical significance (p=0.056) (Figure 5B). Our data show that impaired contextual 
memory reconsolidation triggered by NOP receptor activation is associated with a reduction 
in c-Fos expression in brain regions that support fear memory formation and storage. 
 
3.5 NOP agonist treatment does not inhibit cue-dependent fear memory reconsolidation 
Ro 65-6570 treatment reduces c-Fos expression not only in the hippocampus but also in the 
amygdala. This suggests that NOP agonists might also be able to interfere with amygdala-
dependent hippocampus-independent memory reconsolidation. To test this hypothesis, mice 
were trained to associate an auditory CS to the footshocks in a first context. The next day, 
mice were exposed to the CS in another context in order to reactivate the memory trace. 
Drugs were injected immediately after this retrieval session. Memory strength was evaluated 
24h later, by measuring freezing to the CS in a third context (Figure 6A). Both during 
retrieval and test sessions, the level of freezing was similar between mice treated with vehicle, 
Ro 65-6570 (1 mg/kg) or AT-403 (0.1 mg/kg) (Figure 6B). A two-way repeated measures 
ANOVA revealed no significant interaction between time and drug treatment (F2,22=1.322, 
p=0.287) and no significant effect of time (F1,22=1.612, p=0.217) or drug treatment (F2,22= 
1.344, p= 0.281). Therefore, similarly to their effect on memory consolidation, the NOP 
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agonists tested in this study inhibit selectively the reconsolidation of context- but not cue-
dependent fear memory. 
 
4. DISCUSSION 
Previous studies have shown that NOP agonists negatively regulate memory acquisition and 
consolidation in rodents (Abdel-Mouttalib 2015, Andero 2015). More specifically, i.c.v. 
injection of N/OFQ peptide (Mamiya et al., 2003) or i.p. administration of small molecule 
NOP agonists (Andero et al., 2013; Goeldner et al., 2009) inhibit fear memory acquisition 
and/or consolidation in mice. Our results validate and extend these findings using another 
small molecule agonist, Ro 65-6570 (Wichmann et al., 1999), closely related to the Ro 64-
6198 compound used by Goeldner et al. (Goeldner et al., 2009). These two agonists were 
effective in inhibiting contextual fear memory consolidation at equivalent systemic doses. The 
same doses were inactive on tone fear conditioning thus confirming previous evidence that 
NOP receptor activation was more efficient in interfering with contextual than cued fear 
memory (Fornari et al., 2008; Goeldner et al., 2009; Mamiya et al., 2003). Overall the fact 
that Ro 65-6570 induced amnesia for the conditioning context when injected immediately 
after the acquisition session confirms that systemic treatment with NOP agonists can inhibit 
the consolidation phase of contextual memory. Previous studies have also shown that 
treatment with NOP agonists does not affect the retrieval of hippocampus-dependent 
memories (Fornari et al., 2008; Goeldner et al., 2009; Goeldner et al., 2008). Again, we 
confirm these previous findings in this study by showing that systemic administration of Ro 
65-6570 before re-exposing the animals to the conditioning context does not modify the 
expression of the conditioned freezing behavior. 
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Our demonstration that NOP agonist treatment inhibits fear memory consolidation together 
with previous converging evidence (Andero et al., 2013) suggest that the N/OFQ system 
could be targeted to attenuate traumatic memory, for example in PTSD patients. However, in 
order to validate this hypothesis, it was necessary to study the effect of NOP agonists on the 
memory reconsolidation process for two main reasons. First, in many cases, therapeutic 
interventions occur at a time point when traumatic memory has already been consolidated, 
and therefore it is the reconsolidation phase that is targeted by the treatment (Parsons and 
Ressler, 2013; Schwabe et al., 2014). Second, the consolidation and reconsolidation processes 
show many similarities but also involve distinct molecular mechanisms (Alberini, 2005). For 
example, BDNF down-regulation in the hippocampus (Lee et al., 2004), or blocking of 
histamine H3 or muscarinic receptors in the BLA (Bucherelli et al., 2006), inhibit fear 
memory consolidation but not reconsolidation. Therefore, the main goal of the present study 
was to test whether NOP agonists were able to interfere with aversive memory 
reconsolidation.  
After confirming that NOP agonists were more effective in modulating contextual than cued 
fear memory, we decided to focus initially on the reconsolidation of contextual fear memory. 
We first validated the fact that our memory reactivation procedure (2 min re-exposure to the 
context) was indeed sufficient to destabilize the memory trace. To do so, we used the non-
competitive NMDA receptor antagonist MK-801 which was shown to disrupt contextual fear 
memory reconsolidation after systemic or intra-hippocampal administration (Charlier and 
Tirelli, 2011; Lee and Hynds, 2013). Indeed treatment with MK-801 immediately after 
memory retrieval resulted in a decrease in memory retention when tested 24h later. The main 
observation of the present study is that the NOP receptor agonist Ro 65-6570 produced the 
same amnestic effect. The memory retrieval session was mandatory for Ro 65-6570 to reduce 
freezing to the context and this decrease in freezing could not be attributed to any residual 
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anxiolytic effect. We can therefore conclude that Ro 65-6570 acted by inhibiting the memory 
reconsolidation process. This decrease in memory retention was also observed when animals 
were treated immediately after memory retrieval by either i.c.v. N/OFQ or i.p. AT-403. The 
N/OFQ peptide being an endogenous ligand of the NOP receptor displays very high 
selectivity (Toll et al., 2016). Similarly the recently discovered small molecule agonist AT-
403 is one of the best NOP agonists in terms of potency and selectivity (Ferrari et al., 2017). 
The similar effects of three chemically unrelated NOP-selective ligands thus confirm that the 
NOP receptor is indeed mediating the inhibition of contextual memory reconsolidation 
observed in this study. The effect was achieved with intermediate doses of Ro 65-6570 
compared to its lower anxiolytic (Asth et al., 2016) and higher sedative doses (present rotarod 
results; (Rizzi et al., 2016)). Importantly, doses of Ro 65-6570 and AT-403 that were efficient 
in inhibiting contextual memory reconsolidation had no effect on tone fear memory when the 
drugs were injected immediately after cue-induced memory reactivation. This suggests that 
hippocampus-dependent contextual memory traces are more prone to destabilization by NOP 
agonists than amygdala-dependent simple associations.  
Providing further insights onto the potential cellular mechanisms supporting the effect of Ro 
65-6570 on fear memory reconsolidation, we found that post-retrieval administration of this 
drug reduced c-Fos expression in CA1 and CA3 regions of the dorsal hippocampus. These 
sub-regions are known to be associated with the reactivation and reconsolidation of contextual 
fear memory (Besnard et al., 2014; Hall et al., 2001; Inaba et al., 2015; Mamiya et al., 2009). 
Interestingly, it was recently demonstrated that the inhibition of dorsal CA1 pyramidal cells 
following contextual fear memory retrieval was sufficient to impair memory reconsolidation 
(Lux et al., 2017). Ro 65-6570 could therefore exert a direct inhibitory effect on the plasticity 
of pyramidal hippocampal neurons which express NOP receptors (Mollereau and Mouledous, 
2000; Ozawa et al., 2015). The observed reduction in c-Fos positive neurons could be related 
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to a pre- and/or post-synaptic inhibition of NMDA-dependent plasticity (Bongsebandhu-
phubhakdi and Manabe, 2007; Goeldner et al., 2009; Goeldner et al., 2008; Mamiya et al., 
2003; Manabe et al., 1998). Post-retrieval Ro 65-6570 administration also significantly 
reduced c-Fos expression in the CA1 region of the ventral hippocampus as well as in the 
central part of the amygdala, two regions that are activated following fear memory retrieval 
(Besnard et al., 2014; Chia and Otto, 2013; Hall et al., 2001; Mamiya et al., 2009). At the 
cellular level, the inhibitory effect of the NOP agonist is therefore not restricted to the 
contextual part of the fear memory circuitry but also concerns its emotional part (Izquierdo et 
al., 2016). However it is worth noting that the inhibition was not significant in the BLA which 
is the major region for CS-US association in the fear conditioning paradigm. This is consistent 
with the notion that systemic NOP agonist administration is more efficient in interfering with 
fear memory associated with a context (disruption of hippocampal plasticity) than with 
discrete cues (less efficient disruption of amygdalar plasticity) (Fornari et al., 2008; Goeldner 
et al., 2009; Mamiya et al., 2003). However, NOP receptors are present in the amygdala and, 
similarly to the hippocampus, Ro 65-6570 could produce its effect in this region by interfering 
directly with glutamate signaling (Kallupi et al., 2014). Finally, inhibitory NOP receptors 
expressed in almost all aminergic and cholinergic nuclei (Mollereau and Mouledous, 2000) 
could also exert an indirect modulatory influence on fear memory processing (Izquierdo et al., 
2016). Altogether, post-retrieval Ro 65-6570 silencing effects are consistent with the 
anatomical and functional distribution of NOP receptors and nicely support our behavioral 
data. The strong inhibition observed in the dorsal hippocampus also suggests that NOP 
agonists could be efficient in interfering with the reconsolidation of other types of context-
dependent memories such as drug-induced place preference (Reichelt and Lee, 2013). 
Targeting reconsolidation using pharmacological agents is a promising approach to treat 
pathological memories in humans. Our data suggest that NOP agonists could be used to 
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disrupt some types of maladaptive memories. However more preclinical studies are needed to 
fully validate their usefulness. The magnitude of the effect NOP agonists on contextual fear 
memory was similar to that of the NMDA receptor antagonist MK-801. It was also equivalent 
to the efficacy of the -adrenergic receptor antagonist propranolol reported in the literature 
(Abrari et al., 2008; Muravieva and Alberini, 2010). However, contextual fear memory was 
not fully erased and we could not demonstrate a significant effect when Ro 65-6570 was 
injected before memory retrieval. Further studies are therefore warranted to improve 
treatment efficacy, for example using agonists with a longer duration of action or performing 
additional reactivation sessions. It would also be informative to assess the effect of NOP 
ligands on stronger and older memories and to study the duration of the amnestic effect at 
later time points. Finally, a possible limitation of the usefulness of NOP agonists in the clinic 
comes from the observation of their lack of effect on auditory cue-dependent fear memory 
reconsolidation. However, it is worth mentioning that fear conditioning in rodents does not 
recapitulate all aspects of pathological traumatic memories in humans. Therefore, it is 
difficult to predict drugs’ efficacy in patients simply based on their effect or a lack of effect in 
preclinical models of aversive memory. For example, propranolol treatment led to promising 
results in humans suffering from PTSD or phobia (Kroes et al., 2016) although its effect on 
tone fear memory reconsolidation in mouse has been challenged (Vetere et al., 2013). 
Additional experiments using animal models with better predictive validity are therefore 
needed (Borghans and Homberg, 2015; Bowers and Ressler, 2015).  
In conclusion, this study provides the first demonstration that NOP receptors can be targeted 
to prevent memory reconsolidation. In that sense, it might open new avenues to improve the 
treatment of pathological forms of memories, in particular those associated with impaired 
context processing (Careaga et al., 2016; Liberzon and Abelson, 2016). 
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Supplementary information is available at the Neuropharmacology website. 
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FIGURE LEGENDS 
 
Figure 1. Post-training treatment with Ro 65-6570 inhibits contextual fear memory 
consolidation. (A) Schematic representation of the procedure. FC, fear conditioning; Ro65, 
Ro 65-6570. (B) The percentage of time spent freezing during exposure to the conditioning 
context is significantly reduced in mice treated with 1 mg/kg of NOP agonist immediately 
after conditioning. (C) Freezing to the tone is not affected. Vehicle (n=12), Ro 65-6570 0.1 
mg/kg (n=10), and Ro 65-6570 1 mg/kg (n=8). Bars represent mean ± SEM. *, p<0.05 
compared to vehicle, one-way ANOVA followed by Bonferroni post hoc test.  
 
Figure 2. Post-retrieval treatment with Ro 65-6570 inhibits contextual fear memory 
reconsolidation. (A) Schematic representation of the procedure. CFC, contextual fear 
conditioning; Ro65, Ro 65-6570. (B) The percentage of time spent freezing during exposure 
to the conditioning context is significantly reduced in mice treated with 0.1 mg/kg of NMDA 
antagonist (MK-801) or 1 mg/kg of NOP agonist immediately after memory retrieval. Vehicle 
(n=8), MK-801 0.1 mg/kg (n=8), and Ro 65-6570 1 mg/kg (n=8). (C) Memory retention is not 
affected if the memory retrieval session is omitted. Vehicle (n=8) and Ro 65-6570 1 mg/kg 
(n=8). (D) A lower dose of 0.1 mg/kg of Ro 65-6570 is ineffective. Vehicle (n=8), Ro 65-
6570 0.1 mg/kg (n=8), and Ro 65-6570 1 mg/kg (n=8). (E) Mice treated with 1 mg/kg of Ro 
65-6570 after memory retrieval still show reduced freezing when tested again 7 days after the 
first memory assessment. Vehicle (n=8), Ro 65-6570 1 mg/kg (n=8). Bars represent mean ± 
SEM. *, p<0.05; **, p< 0.01 compared to vehicle, two- (B) or one-way (D) ANOVA 
followed by Bonferroni post hoc test, or unpaired Student t-test (E). 
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Figure 3. Post-retrieval treatment with other NOP agonists inhibits contextual fear 
memory reconsolidation. (A) Schematic representation of the procedure. CFC, contextual 
fear conditioning. (B) The percentage of time spent freezing during exposure to the 
conditioning context is significantly reduced in mice treated with N/OFQ i.c.v. immediately 
after memory retrieval. Vehicle (n=9), N/OFQ 1 nmole (n=9), and N/OFQ 3 nmoles (n=9). 
(C) The percentage of time spent freezing during exposure to the conditioning context is 
significantly reduced in mice treated with the NOP agonist AT-403 i.p. immediately after 
memory retrieval. Vehicle (n=8), AT-403 0.03 mg/kg (n=9), and AT-403 0.1 mg/kg (n=8). 
Bars represent mean ± SEM. *, p<0.05 compared to vehicle, one-way ANOVA followed by 
Bonferroni post hoc test.  
 
Figure 4. Pre-treatment with Ro 65-6570 does not interfere with contextual fear memory 
retrieval. (A) Schematic representation of the procedure. CFC, contextual fear conditioning; 
Ro65, Ro 65-6570. (B) The percentage of time spent freezing during the memory retrieval 
session is similar in mice pre-treated with vehicle or 1 mg/kg of NOP agonist. Mice pre-
treated with Ro 65-6570 show a non-significant decrease in memory retention when tested 
24h later. Vehicle (n=10), Ro 65-6570 1 mg/kg (n=10). Bars represent mean ± SEM.  
.  
Figure 5. Post-retrieval treatment with Ro 65-6570 inhibits neuronal activity in sub-
regions of the hippocampus and the amygdala. (A) Left panel: representative images of c-
Fos staining in the dorsal hippocampus. Scale bar = 50 µm. Examples of positive cells are 
indicated by arrowheads. Right panel: corresponding quantification of c-Fos positive nuclei. 
(B) Quantification of c-Fos positive nuclei in the ventral hippocampus and the amygdala. 
Vehicle (white, n=5), Ro 65-6570 1 mg/kg (black, n=5). Bars represent mean ± SEM of c-Fos 
positive nuclei per mm2. *, p<0.05 compared to vehicle, Student t-test. 
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Figure 6. Post-retrieval treatment with NOP agonists does not inhibit cue-dependent 
fear memory reconsolidation. (A) Schematic representation of the procedure. FC, fear 
conditioning; Ro65, Ro 65-6570. (B) The percentage of time spent freezing during exposure 
to the CS during the test session is similar in mice treated with vehicle or NOP agonists 
immediately after memory retrieval. Vehicle (n=8), Ro 65-6570 1 mg/kg (n=9), AT-403 0.1 
mg/kg (n=8).  
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Supplementary Figure 1. Lack of effect of Ro 65-6570 administration in the elevated 
plus-maze 24h after treatment. There is no difference in the time spent in closed and open 
arms (left) (unpaired t tests, p=0.438 for open arms, p=0.701 for closed arms) nor in the 
number of entries in each arm (right) between vehicle and Ro 65-6570 treated mice (unpaired 
t tests, p=0.831 for open arms, p=0.270 for closed arms). n=9 per group.  
 
 
 
 
 
Supplementary Figure 2. A high dose of Ro 65-6570 affects motor coordination. 
Treatment with 3 mg/kg of Ro 65-6570, but not 1 mg/kg, significantly reduces the time spent 
on the rotarod compared to vehicle-treated mice. ***, p<0.001 compared to vehicle, one-way 
ANOVA followed by Bonferroni post hoc test (F2,18=15.35, p=0.0001). n=7 per group. 
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Highlights 
 Systemic injection of NOP agonists inhibits contextual fear memory reconsolidation 
 NOP agonists inhibit reconsolidation as efficiently as an NMDA receptor antagonist 
 NOP agonists reduce c-Fos expression in the hippocampus following memory retrieval 
 NOP receptors could be targeted to attenuate hippocampus-dependent memories 
 
 
